Comments to the Pharmaceutical Benefits Advisory Committee
Gilead and Alphapharm HIV pre-exposure prophylaxis applications

Executive Summary

Australia’s Seventh National HIV Strategy 2014-2017 sets the framework and direction for Australia’s national response to HIV. The Strategy sets a world-leading goal of virtually eliminating HIV transmission in Australia by 2020, and establishes ambitious targets to reduce HIV infections and increase the percentage of people with HIV on antiretroviral treatment (ART).

Australia has a national, bipartisan commitment to these goals, with all Health Ministers endorsing them in a Council of Australian Governments (COAG) Standing Council on Health communique issued in 2013.

There has been good progress on increasing treatment rates for people living with HIV, but little progress on reducing national infection rates. In 2015 there were 1,025 HIV notifications, with gay and other men who have sex with men accounting for 68 per cent of these diagnoses. This figure is consistent with the trend over the last decade.

In April 2017, another COAG communiqué from Australian Health Ministers recognised Pre-Exposure Prophylaxis (PrEP) as a crucial component for achieving Australia’s goal of virtually eliminating HIV transmission by 2020.

PrEP is potentially a game-changer that will make reaching Australia’s 2020 HIV prevention target possible – but only if PrEP is accessible and affordable for those at high risk of HIV. Both the UK PROUD study and the French and Canadian IPERGAY trials reported 86% reductions in risk of HIV infection among participants using PrEP to prevent HIV. Conservative analysis by the Kirby Institute for Infection and Immunity in Society indicates that making PrEP available to just those gay men at highest risk of acquiring HIV would reduce HIV diagnoses in Australia by 44 per cent in the first 12 months, preventing 332 people from acquiring HIV.

The TGA’s registration of Gilead and Alphapharms’ PrEP medications on the Australian Register of Therapeutic Goods is welcome, but the cost of PrEP remains prohibitive for most people.

The cost of providing PrEP under the PBS to a person for periods they are likely to be at high-risk of acquiring HIV, is likely to be minimal compared to the cost of lifetime treatment of that individual if they acquire HIV. The cost of providing PrEP under the PBS to those at high risk of HIV infection would be more than offset by savings from HIV infections averted.

---

3 Available at: http://www.coaghealthcouncil.gov.au/Portals/0/Final%20CHC%20Communique_24%20March%202017_1.pdf
4 For further information and comment on these studies, see:
   - CDC Statement on IPERGAY Trial of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among Men Who Have Sex with Men (CDC media statement)
   - Pre-exposure prophylaxis (PrEP) stops 86% of HIV infections in PROUD study (aidsmap.com)
   - Pre-exposure prophylaxis also stops 86% of HIV infections in IPERGAY study (aidsmap.com)
   - PrEP Proactive Responsible Empowered Pleasure (Living Positive Victoria media release)
   - PrEP for gay men, serodiscordant heterosexual couples and women (Sean Slavin, AFAO, for ASHM blog)
HIV is a communicable disease, with every infection averted potentially also preventing further onward infections. **PrEP must be recognised as a timely public health intervention** providing not only personal protection from HIV, but also protecting others who might also have acquired HIV had the infection not been averted.

AFAO, AIDS Councils, other community based HIV organisations and research organisations involved in PrEP demonstration projects in Australia are already providing **PrEP education resources** that emphasise the importance of daily adherence and recommend strategies to help users remind themselves to take PrEP.\(^5\) It will be straightforward for these communications to continue once PrEP is added to the PBS.

The PROUD study in particular indicates that **PrEP would be highly effective in a ‘real-world’ setting** similar to trial contexts with community GPs and health clinics providing access to PrEP, and community HIV agencies providing education and support — the way PrEP would be rolled out if it were subsidised under the PBS.

**PrEP will allow for an increase in regular and comprehensive STI testing and treatment.** Social research indicates that there is considerable room to improve comprehensive HIV/sexual health testing rates\(^6\) and the frequency of re-testing. Quarterly STI screening of PrEP users has the potential to significantly increase the early detection and treatment of STIs, and mitigate potential transmission to sexual partners.

PrEP is registered for use in an increasing number of countries and is **recommended by the World Health Organisation as a key HIV prevention tool.**

**PrEP prescribing arrangements need to be straightforward.** There is no clinical basis for placing an s100 restriction on prescribing arrangements for PrEP as the initiation of PrEP and ongoing monitoring is straightforward. Limitations on general practitioners prescribing PrEP may lead to delays in commencing PrEP, resulting in avoidable transmissions.

PrEP should be dispensed through **community pharmacies.**

A **fair price for PrEP** is essential. In the case of the two PrEP applications before PBAC, we believe that the PBS price should be informed by the price being paid by individuals to import PrEP from overseas suppliers of generic PrEP through the Personal Importation Scheme, and the price paid to purchase generic Truvada for clinical access programs in various Australian states.

AFAO, along with the National Association of People with HIV Australia, contributed to the development of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine’s 2017 Guidelines on PrEP. AFAO endorses these guidelines.

There is strong recognition internationally that PrEP is effective and that its delivery needs to be integrated into health systems – to “put the strong and consistent evidence of PrEP efficacy into practice.”\(^7\) PrEP is a powerful HIV prevention tool, and facilitating its use has the **potential to break the cycle of HIV transmission** among gay men in Australia. We have the systems and infrastructure in place – not least through our

---

\(^5\) For example, see EPIC-NSW Information for Participants booklet: http://endinghiv.org.au/nsw/wp-content/uploads/2015/02/EPIC-NSW-Information-for-participants.pdf


\(^7\) “Pre-exposure prophylaxis works – it’s time to deliver”. The Lancet. Vol 385. 18 April 2015, p. 1483.
community organisations and community networks – to integrate PrEP education and health promotion resources into existing education and care programs. Australia has demonstrated the leadership and foresight required to sustain a world-leading public health approach to HIV prevention. **PrEP needs to be listed on the PBS if we are to meet our commitment to virtually eliminating HIV transmission in Australia by 2020.**

**About AFAO**

The Australian Federation of AIDS Organisations (AFAO) is the national federation for the HIV community response. AFAO’s members are the AIDS Councils in each state and territory; the National Association of People Living with HIV Australia (NAPWHA); the Australian Injecting & Illicit Drug Users League (AIVL); the Anwernekenhe National HIV/AIDS Alliance (ANA); and Scarlet Alliance, Australian Sex Workers Association. AFAO advocates for its members, promotes medical and social research into HIV and its effects, develops and formulates policy on HIV issues, and provides HIV policy advice to Commonwealth, state and territory governments.

AFAO welcomes the opportunity to provide comment in support of the applications before PBAC to have HIV PrEP listed on the PBS.

**1. Enhancing access to PrEP is essential if we are to achieve National HIV Strategy goals**

The National HIV Strategy sets a world-leading goal of virtually eliminating HIV transmission in Australia by 2020. It establishes ambitious targets to reduce HIV infection rates and increase the percentage of people with HIV on antiretroviral treatment. In 2013, all members of the Council of Australian Governments Standing Council on Health endorsed these targets, which are drawn from Australia’s commitment to the United Nations Political Declaration on HIV, and in 2014, Australia’s Health Ministers agreed to the goal of virtually eliminating new HIV infections in Australia by 2020. In April 2017, Australian Health Ministers released a joint communique in which they recognised PrEP as crucial to achieving the goal of eliminating HIV by 2020. The communique acknowledged:

> “the importance of the consideration of listing of PrEP on the Pharmaceutical Benefits Scheme to ensure equitable and sustainable access for at-risk individuals in Australia for the prevention of HIV.”

There has been excellent progress on increasing treatment rates for people living with HIV, but little progress on reducing national infection rates. Over the three years from 2013 to 2015, the HIV infection rate in Australia remained stable. In 2015 there were 1,025 HIV infections newly diagnosed, with gay and other men who have sex with men accounting for 68 per cent of those diagnoses.

PrEP is potentially the game-changer that will make reaching the 2020 HIV prevention target possible – but only if it is accessible and affordable for those most at risk of HIV. The most direct and effective means of targeting PrEP to those most at risk of HIV is to list PrEP on the PBS.

---

This submission focuses on how best to ensure that people at high risk of HIV are aware of PrEP as a prevention tool, and how PBS listing of PrEP is essential to efforts to substantially reduce HIV transmission in Australia.

2. Public health savings from infection averted

Aside from the individual benefit, there are considerable cost savings to the public health system from infections averted. A recent estimate of the average cost of treatment and care for one person is approximately $20,000 per year\(^1\). Epidemiological modelling indicates that if Australia achieved the target of 95 95 95\(^2\) alongside a scale up 80% of men who have sex with men at high risk of HIV acquisition on PrEP by 2020, the number of men who will avoid acquiring HIV is: 184 people in the second half of 2017; 489 people in 2018; 613 people in 2019; and 739 people in 2020.\(^3\) This is a total of 2,025 averted HIV infections by 2020.

The cumulative **savings from the infections averted** until 2020 is **$82 million**. The lifetime medical and treatment costs for a person living with HIV are estimated to be $1 million. The savings for preventing lifetime costs from all infections averted until 2020 is over $2 billion.

3. Australia’s gay community is ready for PrEP

Gay community organisations and individual activists have been central to leading Australia’s community response to HIV for over thirty years, working as part of the HIV sector to develop and promote innovative prevention strategies that respond to advances in scientific knowledge and behavioural research. At the same time, community organisations have identified and sought to address structural barriers that can impede the timely adoption and rollout of new prevention strategies.

Over the past four years, there has been concerted advocacy by the HIV community sector toward enhancing access to PrEP in Australia. This advocacy was energised by the announcement at the 2015 International Conference on Retroviruses and Opportunistic Infections, that both the UK PROUD study and the French and Canadian IPERGAY trials had reported 86% reductions in risk of HIV infection among participants using PrEP to prevention HIV.\(^4\)

---

1. This figure for treatment cost has been estimated by Dr Richard Gray from the Kirby Institute, UNSW. This figure is in 2015 dollars and is an average of treatments costs for the total population of HIV positive people who were diagnosed at different points in time. The figures for the different treatment costs come from the AFAO discussion paper: *Estimates of the number of people eligible for PrEP in Australia, and related cost-effectiveness* – attached as Appendix 1.

2. These numbers are 95% of people living with HIV diagnosed, 95% of people living with HIV on treatment and 95% on treatment and with an undetectable viral load. These numbers were adapted from UNAIDS targets.

3. This is based on the assumption that by 2020 95% of all people living with HIV will know their HIV status, 95% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 95% of all people receiving antiretroviral therapy will have viral suppression, which means that they cannot transmit HIV through sexual contact. Attached as Appendix 2 are the figures obtained from econometrician Dr Nick Scott from the Burnet Institute. The data cited here is drawn from that HIV incidence modelling.

4. For further information and comment on these studies, see:
   - CDC Statement on IPERGAY Trial of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among Men Who Have Sex with Men (CDC media statement)
   - Pre-exposure prophylaxis (PrEP) stops 86% of HIV infections in PROUD study (aidsmap.com)
   - Pre-exposure prophylaxis also stops 86% of HIV infections in IPERGAY study (aidsmap.com)
   - PrEP Proactive Responsible Empowered Pleasure (Living Positive Victoria media release)
   - PrEP for gay men, serodiscordant heterosexual couples and women (Sean Slavin, AFAO, for ASHM blog)
These findings indicate that when PrEP is properly targeted to those who are at risk of acquiring HIV, PrEP users will generally continue with whatever risk behaviours and risk reduction strategies they used prior to taking the drug. The PROUD study in particular confirmed that PrEP is highly effective in a ‘real-world’ setting, that is, with participants accessing PrEP through health clinics in the community — the way it would be delivered if it were subsidised under the PBS — not only where access is provided under the highly-controlled clinical trial conditions.

4. PrEP is a key component of combination HIV prevention approaches

As recognised in Australia’s National HIV Strategy, a mixture of behavioural, biomedical and structural approaches will enable us to drive down HIV infection rates. AFAO and its members have mobilised, engaged and educated gay men regarding the 2020 goal of ending HIV transmission and there have been significant achievements in enhancing community health literacy about the need for frequent HIV testing and immediate treatment.

As part of this comprehensive approach to HIV prevention, PrEP has great potential to drive down HIV infection rates among Australian gay men — if it is affordable for those most at risk. Gay men are already accessing affordable PrEP via online personal importation, but a PrEP PBAC listing would provide access to the drug that has been approved by the TGA, with quality assured. PBS listing is essential if this game-changing prevention tool is to be targeted to and available to those most at risk of HIV.

5. Australian gay men have high levels of health literacy

Throughout the HIV epidemic, gay men have demonstrated high levels of health literacy with knowledge continuing to evolve in response to scientific advances. Awareness of PrEP among gay men in Australia has grown rapidly over the past few years and the findings that PrEP has proven effective at reducing HIV infections, particularly in real world settings, has engaged many in the community. In 2015, the Australian PrEPARE survey reported that three quarters of respondents had heard of PrEP. In 2016, a community survey found that 89 per cent of gay men had heard a lot or a little about PrEP, with two thirds of those who had heard of PrEP aware that it is an effective way of preventing HIV infection. Gay and other homosexually active men who have heard of PrEP generally have a positive response to discussion of PrEP.

Australia’s State and Territory AIDS Councils are responding to community interest and have convened many community forums to provide information on PrEP and access options in recent years. There is also considerable community activism and interest with three community groups (PrEPAccessNow, PrEP’D for Change, and Time4PrEP) working to promote and advocate for access, and to support gay men interested in accessing PrEP.

---

17 For more information: http://www.prepaccessnow.com.au
18 For more information: http://prepdforchange.com/home.html
19 For more information search Facebook: ‘Time4PrEP’
6. Gay men at high risk of HIV are willing to use PrEP

The PrEPARE study, which examined gay and bisexual men’s attitudes toward biomedical HIV prevention, has found that 32 per cent of HIV-negative and untested respondents showed a willingness to use PrEP.\(^{20}\)

Real world considerations in making a decision whether or not to use PrEP include perceived self-risk of HIV acquisition, the cost of PrEP, prescribing and dispensing options, and willingness to engage in regular clinical monitoring. When these considerations are taken into account, the proportion of HIV-negative men who may come forward to request PrEP is likely to be significantly smaller than the 32 percent of PrEPARE participants willing to use PrEP, given that a research participant’s willingness to take PrEP does not necessarily translate to an actual decision to use PrEP. In 2014, with uptake mostly limited to personal importation or small demonstration projects, about three per cent of gay or bisexual HIV-negative men with casual sexual partners had used PrEP in the prior six months.\(^{21}\)

Since then, a number of state-based PrEP demonstration projects have begun. The EPIC study in NSW enrolled 4385 gay and bisexual men at high risk of HIV between March and December 2016.\(^{22}\) AFAO understands that as of May 2017 6000 people have enrolled in EPIC. In Victoria, enrolments in the PrEPX study has reached the cap of 3800 people, and in Queensland, QPrEP has enrolled over 1650 of the 2000 places in their study.\(^{23}\) This indicates substantial interest in PrEP among gay and bisexual men at high risk of HIV.

7. Gay men in Australia are already using PrEP

The two means by which gay men in Australia currently access PrEP are by importing generic drugs for personal use via online purchase (Personal Importation Scheme), or by enrolling in a PrEP demonstration project.

- Personal importation: several online pharmacy sites offer generic versions of Truvada for sale. These sites require an Australian-issued doctor’s prescription.
  As discussed above in section 6, demonstration projects are in operation in a number of states and provide PrEP to considerable numbers of gay and bisexual men at high risk of HIV.

There are risks associated with personal importation: the safety and quality of the drugs purchased cannot be guaranteed; and while most sites require a prescription for purchases, there is the potential for drugs to be purchased without a prescription or for a prescription to be reused. There is also potential for patients to access PrEP without regularly seeing a doctor for monitoring and other primary health care.

To facilitate safe use of PrEP, AFAO and its members have posted information on our websites regarding the legality and safety of purchasing PrEP online. These activities constitute a practical effort to inform gay men of PrEP access options and ensure the risk of harm is minimised.


8. Unmet need for PrEP

An AFAO report\textsuperscript{24} estimates that there are 31,347 men who have sex with men at high risk of HIV acquisition who would be eligible for PrEP in Australia. This estimate is based on eligibility criteria contained in the 2017 ASHM Guidelines on PrEP. AFAO supports the ASHM guidelines and believes the eligibility criteria are well-considered and appropriately targeted. They are informed by finely calibrated understandings of HIV-transmission risk drawn from state-based the demonstration projects.

This estimate of 31,347 gay men and other men who have sex with men at high-risk of HIV acquisition indicates considerable need, which will be unmet, if PrEP is not listed on PBS. Current access arrangements are inequitable and will result in avoidable infections.

9. Gay men currently using PrEP in Australia are showing high levels of adherence

While adherence to drug dosage regimens can be challenging, early findings from the PrEP demonstration projects in NSW and Victoria show very high levels of adherence.

The importance of drug adherence is a familiar concept in the gay community. People living with HIV are very aware of the need for drug adherence. HIV-negative gay men, given their contact with people with HIV and overall high levels of HIV health literacy, are also aware that the effective treatment of HIV requires individuals to adhere to the daily dosing regimen. The PrEPARE study found that men who had heard of PrEP tended to know that its efficacy depends on taking the drug as prescribed.\textsuperscript{25} Both VicPrEP and PrELUDE have reported therapeutic drug levels in individuals on PrEP. The VicPrEP study reports high-level adherence rates as assessed by self-reporting questionnaires, refill-based measures and dry-blood-spot assays of drug levels, with 90% of participants assessed as having therapeutic drug levels.\textsuperscript{26}

10. Individuals at risk of HIV infection require affordable access to PrEP

The cost of PrEP remains prohibitive for most Australian gay men. If PrEP is not listed on the PBS, gay men who use PrEP purchased online will continue to do so, and will continue to be exposed to the risks regarding the quality and safety of imported products, and the potential to be disconnected from primary health care.

The burden of PrEP access currently sits with states and territories, an outcome that was never envisaged when the various Australian PrEP clinical trials were established over three years ago. The new PrEP eligibility estimates show a significantly higher number of people can benefit from PrEP than are catered for by the trials. These recently revised estimates reflect the considerable clinical, epidemiological and program knowledge gained since the first Australian PrEP trials commenced.

AFAO is also concerned that some state and territory governments who are supporting clinical trials might be unwilling to continue funding these trials if PBS listing does not occur within a reasonable timeframe. This outcome could lead to further inequitable access based on where people live and their ability to pay.

\textsuperscript{24} AFAO Discussion Paper: Estimates of the number of people eligible for PrEP in Australia, and related cost-effectiveness – attached as Appendix 1.
\textsuperscript{25} Holt M, Lea T, Kippax S, et al. Awareness and knowledge of HIV pre-exposure prophylaxis among Australian gay and bisexual men: results of a national, online survey. Sexual Health. Advance online publication. 2016. \url{http://dx.doi.org/10.1071/SH15243}
From the PrEPARE study we know that gay men who perceive themselves to be at risk of HIV are more likely to be willing to use PrEP, that is, those who engage in condomless sex with casual partners, who have previously taken post-exposure prophylaxis or who have an HIV positive regular partner. The PrEP demonstration projects have found that they are diagnosing HIV infections during enrolment, indicating that at-risk individuals are self-selecting for PrEP.

11. PrEP is likely to be used for periods of time when an individual’s risk of HIV infection is higher.

Gay men’s sexual practices, as for most adults, vary through life. Gay men who do choose to take PrEP are likely to use it only for periods when their risk of HIV transmission is elevated, that is, for periods of time rather than continuously throughout adult life. There will be in most people’s lives periods of sexual inactivity, periods in monogamous relationships, and other periods when a person may be sexually active with casual partners. PrEP is most useful for those individuals who recognise that their risk is elevated at certain points, and who regard PrEP as providing the best available protection against HIV during those periods.

The cost of providing PrEP to a person during periods when they are at high-risk of acquiring HIV is minimal when compared to the lifetime treatment and medical costs incurred by individuals living with HIV. AFAO is cognisant of the cost-benefit consideration that PBAC is required to make. As discussed in section 2, on the basis of 80% of men who have sex with men at high risk of HIV acquisition being on PrEP by 2020, the number of men who will avoid acquiring HIV is: 184 people in 2017; 489 people in 2018; 613 people in 2019; and 739 people in 2020. The cumulative savings from the infections averted for this group of men until 2020 is $82 million. Given that lifetime medical and treatments costs for HIV are estimated to be $1 million, the potential savings for the health budget are $2 billion.

We strongly encourage PBAC to recognise the nature of HIV as a communicable disease. Every HIV infection averted prevents onward transmission. In this way, PrEP must be considered as a public health intervention providing not only personal protection from HIV, but also as an intervention that has a population wide impact of protecting others who might also have acquired HIV had the infection not been averted. AFAO urges PBAC to consider the cost-effectiveness of PrEP at both the individual and the population level, since it is at both levels that Australia will benefit from this intervention. Rapid-scale of PrEP is required to maximise PrEP’s impact as an HIV prevention tool. This rapid scale up can only be achieved if PrEP is access through the PBS.


28 This is based on the assumption that by 2020 95% of all people living with HIV will know their HIV status, 95% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 95% of all people receiving antiretroviral therapy will have viral suppression, which means that they cannot transmit HIV through sexual contact. Attached as Appendix 2 are the figures obtained from econometrician Dr Nick Scott from the Burnet Institute, Victoria. The data cited here is drawn from that HIV incidence modelling.
12. Gay men have the health literacy to make informed decisions about the risks associated with PrEP use

Throughout the HIV epidemic gay men have shown high levels of health literacy regarding HIV which have informed individual decisions about prevention strategies. PrEP does present some risks, particularly if the dosing regimen is not adhered to; however, there are inherent risks in the variety of strategies gay men use to prevent HIV infection, including, for example, incorrect or inconsistent use of condoms. This has not discouraged men from assessing HIV risk and making a personal decision that is appropriate for them. The very nature of the HIV risk has required gay men to balance their natural, human wish for intimacy with the potential for acquiring HIV. Gay men have made considered HIV risk calculations for more than thirty years, and will continue doing so, weighing up the benefits that PrEP may offer against the risks it may pose.

Side effects for people using PrEP are usually transient. For sexually active gay men who use PrEP, ongoing clinical care will help with the management of any side effects, adherence and STI screening.

To ensure the effectiveness of PrEP for individual users and as a prevention strategy to drive down HIV infection rates among gay men, there will need to be significant efforts to promote awareness of the importance of adherence to dosing regimens. Consultations for prescription repeats will present a face-to-face opportunity to reinforce the importance of adherence and for regular STI testing. This will complement community organisations’ education and health promotion programs. AFAO, AIDS Councils and research organisations running the demonstration projects are already providing PrEP communication resources that emphasise the importance of daily adherence and recommend strategies to help users remind themselves to take PrEP.29 It will be straightforward for these communications to continue once PrEP is added to the PBS.

13. The gay community will adapt prevention strategies to incorporate PrEP

Some concern has been expressed about the potential impact of PrEP on sexual behaviour, particularly the impact it may have on rates of condomless anal sex among PrEP users.

Although overall rates of condom use during anal intercourse with casual partners have remained high, gay men have found a variety of ways to reduce the risk of HIV infection if they are not using condoms. These risk reduction strategies include: ‘serosorting’ (having sex with men of the same HIV sero-status); ‘strategic positioning’ (for example, the HIV negative partner taking the insertive position during anal intercourse); ‘negotiated safety’ (condomless sex within relationships); monitoring viral load (with condomless sex when viral load is undetectable); and post-exposure prophylaxis. PrEP will augment these existing risk reduction strategies.

It needs to be acknowledged that concerns regarding the ‘risk’ of condomless sex can be moralistic and homophobic, with gay men being told that a desire to use PrEP equates with complacency about HIV. Sex without condoms occurs because it is generally more pleasurable and intimate; gay men are no different in this respect to other sexually active adults. Just as the contraceptive pill enabled women to have condomless sex while being protected against pregnancy, PrEP enables gay men who may not always be using condoms to guard against HIV infection.

29 For example, see EPIC-NSW Information for Participants booklet: http://endinghiv.org.au/nsw/wp-content/uploads/2015/02/EPIC-NSW-Information-for-participants.pdf
Gay men are adapting to PrEP just as they have adapted to other developments. Whatever choices gay men make, it is up to each sexually active gay man and his sexual partners to make decisions about HIV risk and safety. PrEP is alleviating many men’s fear of acquiring HIV, a fear that has been present throughout most gay men’s sexual lives. As outlined above (section 3), findings from both the UK PROUD study and the French and Canadian IPERGAY trials indicate that when PrEP is properly targeted, users will generally continue with whatever risk behaviours and risk reduction strategies they used prior to taking the drug. Neither the PROUD nor the IPERGAY study found evidence of increased sexual risk taking. The PROUD study, in particular, indicates that PrEP would be highly effective in a ‘real-world’ setting similar to trial contexts with community GPs and health clinics providing access to PrEP, and community HIV agencies providing education and support — the way PrEP would be rolled out in Australia if it were subsidised under the PBS.

14. **PrEP will allow for an increase in regular and comprehensive STI testing and treatment**

Early findings from the PrEP demonstration projects in Victoria and NSW are showing a decline in condom use; this is entirely expectable as PrEP offers sufficient protection from HIV that condoms are not additionally required for protection unless a person’s sexual partner indicates a wish to use them. Trial participants were already having condomless sex prior to starting on the trials and although some men’s consistent use of condoms may have dropped further while participating in the trial, PrEP provided them with protection from HIV. Additionally, these studies only tell us about the impact of condom use among participants of the study, not the overall impact PrEP may have on condom use within the gay community. The studies highlight the importance of ensuring that PrEP is accessible to those who are already having some condomless sex and whose risk is already elevated.

Testing guidelines recommend that gay men and other men who have sex with men who engage in sexual risk behaviours test for HIV and other STIs up to four times a year. Social research indicates that there is considerable room to improve comprehensive HIV/sexual health testing rates and the frequency of re-testing. Quarterly STI screening of PrEP users has the potential to significantly increase the detection and treatment of STIs, to integrate sexual health monitoring into overall health care and mitigate potential transmission of STIs to sexual partners.

15. **PrEP is registered for use in an increasing number of countries and is recognised by WHO as a key HIV prevention tool**

PrEP has been registered for use in the USA, France, South Africa, Kenya, Israel, Canada and Peru.

France is the first and only country with a centrally organised, reimbursable health system to approve PrEP. The National Health Service England (NHS England) has determined it would not make PrEP available under the NHS because the NHS does not have responsibility for commissioning HIV prevention services. Kenya recently announced that it will be providing publicly subsidised access to PrEP across the country.

---

33 See https://www.england.nhs.uk/2016/05/prep-provision/
In November 2015, the World Health Organization (WHO) released its Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, recommending PrEP for all populations at substantial risk of acquiring HIV. The WHO Guidelines recommend that PrEP be used as part of a combination of HIV prevention approaches.

Within the Asia Pacific region, there is increasing action to prepare for PrEP. The Asia Pacific Coalition on Male Sexual Health, with support from UNAIDS and WHO, has developed actions under the PrEParing Asia banner, setting out advocacy and delivery strategies, including specific roll-out action plans for six countries.

16. PrEP prescribing and dispensing arrangements need to be flexible

Most gay men access their primary healthcare, including their sexual health care, via their local GP rather than with an authorised s100 prescriber or specialist doctor. If PrEP is to be targeted to people most at risk of acquiring HIV, there must be no unnecessary barriers to obtaining a prescription.

Restricting who can prescribe PrEP, for example to specialists and doctors who are trained and accredited section 100 HIV treatment prescribers under current arrangements, would present a significant barrier for people who cannot access one of these clinicians or a sexual health clinic, including people in rural and regional areas. Some States and Territories have very low numbers of s100 treatment prescribers and they, as well as specialist doctors, are generally clustered in metropolitan areas. This would effectively make access to PrEP unavailable for a gay man at high risk in an area with no s100 treatment prescribers, relevant specialists or sexual health services.

There is no reasonable clinical basis for requiring the same s100 training and accreditation arrangements for prescribing PrEP as those that apply for prescribing of HIV treatments. Prescribing PrEP is not clinically complex, and decisions about prescribing are well within routine standards of clinical practice for general practitioners. Restricting prescribing to current s100 arrangements in place for HIV treatment drugs, would dislocate patients from their existing care arrangements, increase the fragmentation of care – with sexual health care being sought separately from other primary health care, or result in patients who need access to PrEP being unable to access it. For the impact of PrEP to be maximised and for its public health benefits to be realised, prescribing arrangements should facilitate its delivery to people at the highest risk of HIV. This is vital if PrEP access is scaled up to ensure that the estimated number of men who are eligible for PrEP can access it.

PrEP should be dispensed through community pharmacies. Limitations on who can dispense PrEP will lead to unnecessary and avoidable transmissions. Like restrictions on prescribing ARV treatment, restricting those who can dispense PrEP, for example to hospital pharmacies, would present a significant barrier for people who do not have access to hospitals, including many people in rural and regional areas and some Aboriginal and Torres Strait Islander people who reside in remote communities.

17. A fair price for PrEP can be negotiated

The Australian Government should rightly be concerned to achieve a fair price for PrEP.

---

Truvada, the patented drug approved for use as PrEP on the ARTG was approved for the treatment of HIV infection on the ARTG in 2004. The provision of Truvada as PrEP for HIV prevention purposes provides an opportunity for the negotiation of a fair price with its manufacturer. AFAO considers that a reasonable price should be lower than the price negotiated for its treatment use, given the purpose of its use is different, it is not a new drug and the recovery of research and development costs by its manufacturer will have been satisfied through its HIV treatment indications.

In relation to Alphapharm’s submission, AFAO considers a fair price to be one that is informed by the price being paid by individuals to import PrEP from overseas suppliers of generic PrEP through the Personal Importation Scheme, and the price paid to purchase generic Truvada for clinical access programs in various Australian states.

18. Proposed PBS clinical criteria

Australia has excellent HIV epidemiological data and clinicians have access to expert guidance on PrEP prescribing. This year, ASHM approved the 2017 ASHM Guidelines on PrEP. This guidance is available to clinicians to inform their decisions about whether patients should be prescribed PrEP, and PBAC should take comfort from the availability of this guidance. AFAO contributed to the development of ASHM’s 2017 Guidelines on PrEP and endorses these Guidelines.

19. From PBAC approval to access through PBS

The PBAC should take all necessary steps to ensure that PrEP is accessible through the PBS as quickly as possible.

20. Providing PBS access to PrEP can help end HIV transmission in Australia

There is strong recognition internationally that PrEP works and that its delivery needs to be integrated into health systems – to “put the strong and consistent evidence of PrEP efficacy into practice.”

Australia has a national, bipartisan commitment to the virtual elimination of HIV transmission in Australia by 2020. PrEP is a powerful HIV prevention tool, and facilitating its use has the potential to break the back of HIV transmission among gay men in Australia. With effective targeting of gay men most at risk of HIV and with equitable access for others at high risk of HIV, Australia can dramatically drive down HIV infection rates. We have the systems and infrastructure in place – not least through our community AIDS Councils and community networks – to integrate PrEP education and health promotion resources into existing education and care arrangements.

Access to PrEP in Australia is inconsistent. To ensure PrEP access is affordable and equitable, PrEP needs to be listed on the PBS.

APPENDIX 1

Discussion paper: Estimates of the number of people eligible for PrEP in Australia, and related cost-effectiveness.

Kirby Institute and the Centre for Social Research in Health

UNSW Sydney

February 2017
Prepared for the Australian Federation of AIDS Organisations (AFAO)
Table of contents

1 INTRODUCTION .................................................................................................................. 15

2 ESTIMATING THE POPULATION ELIGIBLE FOR PrEP ...................................................... 15
   2a Background...................................................................................................................... 15
   2c Updated 2017 estimation of PrEP eligibility................................................................. 17

3. COST-EFFECTIVENESS ANALYSES.................................................................................. 22
   3a. Possible proportions of gay men receiving PrEP.......................................................... 22
   3b. Cost-effectiveness......................................................................................................... 23
       (i) Brief summary of methods ...................................................................................... 23
       (ii) Projected impact of PrEP on reductions in new HIV infections............................... 24
       (iii) Cost-effectiveness considering different PrEP usage scenarios........................... 24
       (iv) Variation in cost-effectiveness estimates considering scenarios of unit cost, adherence, usage patterns, speed of scale up and condom use .............................................................. 26
           a. Unit cost: ............................................................................................................... 26
           b. Adherence: .......................................................................................................... 26
           c. Scale up duration: ............................................................................................... 26
           d. Condom use ........................................................................................................ 26
1 INTRODUCTION

This discussion paper lays out estimates of eligibility for HIV pre-exposure prophylaxis (PrEP) in gay men in Australia, following the Australasian Society for HIV Medicine (ASHM) Australian Commentary on the US Public Health Service Clinical Practice Guidelines on Prescribing PrEP (http://arv.ashm.org.au/arv-guidelines/prep-resources-for-clinicians). These guidelines are hereafter referred to as the ASHM commentary. The document also lays out cost-effectiveness estimates based on these eligibility estimates and scenarios of coverage, adherence and pace of scale up. Given the lack of precise estimates of some at-risk populations, it also provides information on the plausible ranges of these estimates.

The main purpose of this document is to provide the latest available estimates to inform the work of stakeholders working in this field, including but not limited to advocacy organisations, policy makers, funders, the pharmaceutical industry, the TGA and the PBAC.

2 ESTIMATING THE POPULATION ELIGIBLE FOR PrEP

2a Background

Following the approval by the US FDA of HIV PrEP in July 2012, the US Centres for Disease Control (CDC) published PrEP clinical practice guidelines in 2014. These guidelines recommended HIV PrEP consisting of co-formulated tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for adults at “substantial risk” of HIV infection. Among men who have sex with men, this was loosely defined by the CDC as those with an HIV positive partner, or with a recent bacterial sexually transmitted infection (STI), or with a high number of sex partners, or with a history of inconsistent or no condom use, or with a history of commercial sex work. Initial US estimates were that this would comprise about 25% of sexually active men who have sex with men (Smith et al., 2015). A 2014 study in San Francisco based on local behavioural surveillance data estimated that 64% of HIV negative sexually active men who have sex with men in that setting would meet the CDC PrEP criteria, but that only 15% of these men were actually using PrEP (Snowden et al., 2017).

Australian researchers and clinicians first considered state-based PrEP guidelines soon after the publication of the CDC guidelines in 2014. In NSW, a multi-disciplinary group was tasked by NSW Health with developing state-based guidelines. The researchers, clinicians and community representatives on this group were concerned that the US behavioural PrEP eligibility criteria for men who have sex with men were too widely defined and did not adequately contextualise high HIV risk behaviour. Initial guidelines used data on HIV incidence from Australia’s most recent HIV risk factor cohort study, the Health in Men cohort (HIM) study conducted in Sydney, NSW (Poynten et al., 2010). Although follow-up in that study ceased in 2007, the annual number of diagnoses in MSM in NSW has remained roughly stable. In the HIM study, the HIV incidence in sexually active gay men overall was 0.78 per 100 person years, but there were easily identifiable subgroups of gay men who had an incidence of HIV of at least 2% per year (the subgroup with the highest
HIV incidence was men with a diagnosis of rectal gonorrhoea in the last 6 months, who had an HIV incidence of 7.0 per 100 person-years (Jin et al., 2010). These data were then adjusted to form clinically meaningful and easily measureable risk behaviours which could comprise a pragmatic definition of high-risk which would determine eligibility, as outlined in Table 1 below.

Table 1: Factors associated with high risk of HIV acquisition among MSM in the Health in Men (HIM) study, Australia, 2001-07, and their translation into eligibility criteria for PrEP in Australia1.

<table>
<thead>
<tr>
<th>Findings of the HIM study</th>
<th>PrEP eligibility criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-risk factor</td>
<td></td>
</tr>
<tr>
<td>HIV incidence per 100 person years (95% confidence interval)</td>
<td>A regular sexual partner of an HIV-infected man (not on treatment and/or detectable viral load) with whom condoms were not consistently used in the last three months</td>
</tr>
<tr>
<td>A regular sexual partner of an HIV-positive man with whom condoms were not consistently used in the last six months</td>
<td>5.36 (2.78-10.25)</td>
</tr>
<tr>
<td>At least one episode of receptive unprotected anal intercourse with any casual HIV-infected or unknown HIV status male partner during the last six months</td>
<td>2.31 (1.48-3.63)</td>
</tr>
<tr>
<td>Rectal gonorrhoea diagnosis in last six months</td>
<td>7.01 (2.26-21.74)</td>
</tr>
<tr>
<td>Rectal chlamydia diagnosis in last six months</td>
<td>3.57 (1.34-9.52)</td>
</tr>
<tr>
<td>Methamphetamine use in last six months</td>
<td>1.89 (1.25-2.84)</td>
</tr>
<tr>
<td>Rectal chlamydia or infectious syphilis diagnosis in the last three months or at screening for PrEP</td>
<td>Rectal gonorrhoea, rectal chlamydia or infectious syphilis diagnosis in the last three months or at screening for PrEP</td>
</tr>
<tr>
<td>Rectal gonorrhoea, rectal chlamydia or infectious syphilis diagnosis in the last three months or at screening for PrEP</td>
<td>Rectal gonorrhoea, rectal chlamydia or infectious syphilis diagnosis in the last three months or at screening for PrEP</td>
</tr>
<tr>
<td>Rectal gonorrhoea, rectal chlamydia or infectious syphilis diagnosis in the last three months or at screening for PrEP</td>
<td>Rectal gonorrhoea, rectal chlamydia or infectious syphilis diagnosis in the last three months or at screening for PrEP</td>
</tr>
</tbody>
</table>

1Table adapted from draft ASHM HIV Pre-Exposure Prophylaxis: Clinical Guidelines, 2017 (See also Box 1)

At the outset, it was recognised that in defining high risk there were differences between research-measured risk factors such as in the HIM study data and clinically pragmatic measures of high risk. The most important of these differences was that while the research and behavioural surveillance measures generally related to a 6-month period, clinicians recommended that measures for clinical use should relate to a 3-month period to facilitate assessment and initiation of PrEP, and follow up with 3 monthly monitoring and drug supply. This means that exact estimates of the populations at high-risk are not possible as some form of assumption is required to make the data from Australian behavioural surveillance data fit the data required for estimation of clinically meaningful “high-risk” groups. Using a 3 month period of risk instead of the research-based 6 month period of risk would tend to lead to some over-estimation of populations at risk of PrEP.


In 2015, the Kirby Institute undertook estimates of the number of gay men in Australia at high risk to HIV infection eligible for PrEP. These estimates were based on definitions of high HIV risk
contained in the NSW PrEP guideline which were later adapted for ASHM’s clinical guidance. The initial estimates were based on the following data points and calculations.

1. The Australian Bureau of Statistics (ABS) reports the population of males aged 16 to 69 in 2015 to be 8,287,110.
2. In the population-based Second Australian Study of Health and Relationships (ASHR2, conducted in 2012-2013), the proportion of men aged 16 to 69 who identified as gay was 1.88%, equivalent to 155,798 gay men in 2015. (Men who identified as bisexual (1.3% of the sample) were not included in estimates of PrEP eligibility, because it was felt that such men would be much less likely to be prepared to present to a doctor and discuss their homosexual behaviour in a way which would be required for PrEP access. In addition, behavioural data on bisexual men, while being relatively limited, suggest that bisexual men have lower HIV risk behaviour than gay-identifying men. In EPIC-NSW, 95% of participants identify as gay compared to 4% who identify as bisexual (unpublished data), further supporting the presumption that few bisexual men will present for PrEP).
3. At the end of 2014, 20,537 MSM were living with HIV (uncertainty range 18,797 – 22,892)
4. In ASHR2, among gay-identified men aged 16 to 69, 81.9% reported same-sex sexual experiences in the last 12 months, leaving 110,779 sexually active HIV negative gay men.

Further calculations of numbers of men eligible for PrEP are based on this estimate of 110,779 sexually active HIV negative gay men aged 16-69 in Australia in 2015. Estimates of gay men in categories who have specific risk criteria were based on behaviours and STI history reported by sexually active men in the gay community periodic surveys (GCPS). The GCPS forms the basis of Australia’s behavioural surveillance for HIV risk behaviours. Surveys are conducted in gay community settings in the major cities of Australia annually or biennially, and data used in this report were from 2015 or the most recent year for those jurisdictions which do not conduct the survey annually.

As receipt of PrEP under the guidelines was conditional on the likelihood that risk behaviour would continue (and was not only in the past), it was felt that a measure of likely future behaviour was required. There was no direct research measure of this measure of future behaviour, but in the 2015 estimates Australian Gay Community Periodic Survey data on having at least 10 casual partners in the last 6 months were used in the estimates as a rough indicator of men who may be likely to have continuing risk. This is likely to have led to a degree of under-estimation of the populations at risk (some men who acquire HIV have fewer than 10 casual partners in a 3- or 6-month period).

Using this methodology, and based on the behavioural risk factors based in table 2, Kirby estimated that 12% of sexually active gay men in Australia would be eligible for PrEP (equivalent to 13,293 men). This figure was used as a key input to estimate the number of high risk MSM eligible for PrEP through access studies commenced in 2016 in NSW (EPIC), Victoria (PrEPX) and Queensland (QPrEP).

2c Updated 2017 estimation of PrEP eligibility

To inform future PBAC submissions and further initiatives to provide PrEP in Australia, the Kirby Institute and the Centre for Social Research on Health has developed a new estimate of the number of MSM at high risk of HIV. The key change has been to modify the criteria to be more clinically
pragmatic, and less restrictive using updated data sources. This has drawn on a number of inputs including the following

1. Experience from Australian clinical access studies currently providing PrEP to around 7000 individuals at high risk to HIV in NSW, Victoria and Queensland. The most advanced of these, EPIC-NSW, has thus far recruited about 900 participants more than the original estimate of 3700 and continues to recruit 50-80 new participants each week, albeit at a rate greatly reduced from the rate in early 2016 when 100-150 participants per week were enrolled. Victoria has reached its estimate of 2600 participants in the PrEPX study and the study is being expanded to allow more enrolment.

2. Experience from comparable settings who are rapidly rolling out PrEP, notably in France, and the USA (California, New York, Washington State) that in 2015-2016 roll-out of PrEP to gay men had considerably accelerated.

3. Draft updated PrEP eligibility criteria contained in clinical guidance provided by ASHM which recommended more practitioner discretion in applying the high-risk guidelines (see Box 1)

4. WHO guidelines, which recommend PrEP in populations with an HIV incidence of 3% per year or more. In fact, we chose risk groups, based on HIM study data, with an annual HIV incidence of more than approximately 2%, as there are few easily-identifiable subgroups of gay men with an incidence of more than 3%.

5. The position of PBAC in the response to Gilead’s unsuccessful PBAC PrEP submission that further applications for PrEP listing on the PBS should not seek to unreasonably limit the eligible population.

In addition, new estimates of MSM living with HIV were released in the Kirby Institute 2016 annual surveillance report (ASR), and these were 7.1% lower than those in the 2015 ASR. These estimates were that an estimated 19,097 MSM were living with HIV (uncertainty limits of 16,944 – 21,341), leaving a central estimate of 136,701 HIV negative gay men.

In summary, these new eligibility estimates are substantially higher than the previous estimates, relating to the adjustments of initial calculations in the table below, the use of more updated risk estimates from the gay community periodic surveys (GCPS).
Table 2: Differences between 2015 estimates of PrEP eligibility and updated estimates

<table>
<thead>
<tr>
<th>Initial 2015 estimates of high-risk gay men eligible for PrEP (based on available 2014/15 data)</th>
<th>Updated estimates of high-risk gay men eligible for PrEP (based on 2015/16 data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population of MSM living with HIV</td>
<td>Population of MSM living with HIV</td>
</tr>
<tr>
<td>20,537 (Kirby ASR 2015)</td>
<td>19,097 (Kirby ASR 2016)</td>
</tr>
<tr>
<td>Population of sexually active HIV negative MSM aged 16-69</td>
<td>Population of sexually active HIV negative MSM aged 16-69</td>
</tr>
<tr>
<td>110,779</td>
<td>111,953</td>
</tr>
</tbody>
</table>

Risk behaviour requirements (last 6 months, from gay community periodic surveys)

<table>
<thead>
<tr>
<th>Requirement for ongoing risk</th>
<th>For each category below, men also were required to have at least 10 casual partners in the last 6 months</th>
<th>No requirement: it is assumed that men who have the risk factors below are likely to have ongoing risk.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receptive condomless anal intercourse with casual partners</td>
<td>Often</td>
<td>&gt;= one episode (15.4%)</td>
</tr>
<tr>
<td>Methamphetamine use</td>
<td>Monthly or more</td>
<td>&gt;= once (9.2%)</td>
</tr>
<tr>
<td>CLAI with regular partner who has detectable viral load</td>
<td>At least once</td>
<td>At least once (no change) (0.1%)</td>
</tr>
<tr>
<td>Anal STI or syphilis</td>
<td>Any STI</td>
<td>Any STI plus a rectal swab or a syphilis test (10.5%)</td>
</tr>
</tbody>
</table>
Results

Number of gay men eligible for PrEP under high-risk criteria

<table>
<thead>
<tr>
<th></th>
<th>13,293</th>
<th>31,347</th>
</tr>
</thead>
</table>

Percent of sexually active gay men eligible for PrEP under high-risk criteria

<table>
<thead>
<tr>
<th></th>
<th>12%</th>
<th>28%</th>
</tr>
</thead>
</table>

**Medium risk:** The draft *ASHM HIV Pre-Exposure Prophylaxis Clinical Guidelines, 2017* also contain two medium risk criteria. The guidelines recommend that PrEP be considered in men reporting these behaviours. These are

1. Reporting more than one episode of anal intercourse during the last 3 months when condoms broke or slipped off during intercourse (HIV incidence in HIM of 1.3 per 100py).
2. For uncircumcised men only, having at least one episode of insertive condomless anal intercourse where the serostatus of partner is not known or is HIV-positive (HIV incidence in HIM of 1.7 per 100 person-years).

There are difficulties in estimating the proportion of the population who would fit these categories. Regarding condom breakage, data on breakage during anal intercourse in Australia are sparse. Unpublished data from the Health in Men study suggest this occurs in about 1% of HIV negative gay men in a 6 month period, but this is almost entirely in men who report one of the high-risk criteria above. Thus this criterion is unlikely to add substantially to the total pool of men requiring PrEP, unless condom breakage/slippage is over-reported.

Based on reasonable estimates of the proportion of uncircumcised men, which is much higher in younger than older adults, about 2% of gay men might fit into this category, but again, many of these men are likely to report a high-risk behaviour. Overall, it is unlikely that more than 4% of sexually active gay men would fit into this medium-risk category.

**Heterosexual people and injecting drug users:** The draft ASHM HIV Pre Exposure Prophylaxis Clinical Guidelines, 2017 recommend PrEP in heterosexual people and injecting drug users only in very limited circumstances. These are likely to involve very small numbers and we have not made formal estimates of eligibility under these criteria.
Box 1: Risk criteria for MSM to identify their eligibility for PrEP, from DRAFT 2017 Australasian Society for HIV Medicine HIV Pre-exposure Prophylaxis Clinical Guidelines.

| A. High risk – recommend prescribing daily PrEP if the patient acknowledges |
|---|---|
| **Having had any of the following in the last 3 months** | **AND** | **Being likely to have in the next 3 months** |
| • At least one episode of condomless anal intercourse with a regular HIV + partner (not on treatment and/or detectable viral load) | **(indicating sustained risk)** |
| • At least **one** episode of receptive CLAI with any casual HIV + male partner or a male partner of unknown status | • Multiple events of condomless anal intercourse (CLAI) |
| • Rectal gonorrhoea, rectal chlamydia or infectious syphilis diagnosis (during the last 3 months or at screening for PrEP) | • With or without sharing intravenous drug equipment |
| • Methamphetamine use which may lead to an increased risk of HIV acquisition | |
| **AND** | **Being likely to have in the next 3 months** |
| **(indicating sustained risk)** | • Multiple events of condomless anal intercourse (CLAI) |
| **(indicating sustained risk)** | • With or without sharing intravenous drug equipment |

| B. Medium risk – consider prescribing daily PrEP, based on case by case approach if discussion reveals |
|---|---|
| **Having had any of the following in the last 3 months** | **AND** | **Being likely to have in the next 3 months** |
| • More than one episode of anal intercourse when proper condom use was not achieved (e.g. condom slipped off or broke) where the serostatus of partner was not known, or was HIV + and not on treatment or with a detectable viral load | **(indicating sustained risk)** |
| • (if patient uncircumcised) more than one episode of insertive CLAI where the serostatus of partner was not known, or was HIV + and not on treatment or with a detectable viral load | • Multiple events of condomless anal intercourse (CLAI) |
| **Case by case approach** | • With or without sharing intravenous drug equipment |

If, based on a complete sexual and drug-using history, and the personal circumstances of the patient, the doctor is of the opinion that they are likely be at high-risk of HIV, then PrEP prescription may be considered despite the absence of the high- or medium risk factors above.
3. COST-EFFECTIVENESS ANALYSES

3a. Possible proportions of gay men receiving PrEP

A range of scenarios are possible with respect to use of PrEP at the population level. As the likely numbers of recipients who receive PrEP on the basis of heterosexual behaviour or IDU is believed to be small, we have confined these analyses to gay identifying men. We do not believe high levels of uptake are likely in bisexual men (1.3% of adult males aged 16-69), for reasons outlined above, and as supported by the fact that only 4% of participants in EPIC NSW enrolled in 2016 identified as bisexual. The following categories were developed. Although further categories could be added, we believe this gives us a reasonable range based on current calculations of those at risk.

Table 3: PrEP usage scenarios for cost-effectiveness analysis.

<table>
<thead>
<tr>
<th>PrEP usage scenarios</th>
<th>Percentage of high risk gay men who receive PrEP (approximately 28% of gay men)</th>
<th>Percentage of medium risk gay men who receive PrEP (approximately 4% of gay men)</th>
<th>Percentage of all other gay men who receive PrEP. (approximately 68% of gay men)</th>
<th>Scenario name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use only in high-risk gay men, lowest uptake</td>
<td>30%</td>
<td>0%</td>
<td>0%</td>
<td>Scenario30-0-0</td>
</tr>
<tr>
<td>Use only in high-risk gay men, medium levels of uptake</td>
<td>60%</td>
<td>0%</td>
<td>0%</td>
<td>Scenario60-0-0</td>
</tr>
<tr>
<td>Use only in high-risk gay men, highest plausible uptake</td>
<td>90%</td>
<td>0%</td>
<td>0%</td>
<td>Scenario90-0-0</td>
</tr>
<tr>
<td>High uptake in high risk, low uptake in medium risk</td>
<td>90%</td>
<td>20%</td>
<td>0%</td>
<td>Scenario90-20-0</td>
</tr>
<tr>
<td>High uptake in high risk, medium-high uptake in medium risk</td>
<td>90%</td>
<td>60%</td>
<td>0%</td>
<td>Scenario90-60-0</td>
</tr>
<tr>
<td>High uptake in high risk, some uptake in both medium and low uptake</td>
<td>90%</td>
<td>20%</td>
<td>10%</td>
<td>Scenario90-20-10</td>
</tr>
<tr>
<td>High uptake in high risk, higher uptake</td>
<td>90%</td>
<td>60%</td>
<td>30%</td>
<td>Scenario90-60-30</td>
</tr>
</tbody>
</table>
in medium and low risk
90% of gay men use PrEP, regardless of risk
90%  90%  90%  Scenario90-90-90

3b. Cost-effectiveness
The detailed methods used to determine cost-effectiveness of PrEP as a public health intervention are detailed in the Appendix. The following is a brief summary. All monetary values are given in Australian dollars.

(i) Brief summary of methods
- We developed a HIV transmission mathematical model and determined what impact PrEP would have on reducing HIV among Australian gay men in a range of usage scenarios (Table 3) and willingness to pay thresholds, and initially assumed the following: 1) PrEP unit cost is $10,249; 2) scale up occurred over a 3-year period; 3) high adherence (90%) resulting in very high efficacy (99%) and 4) no reduction in condom use.
- We assumed the current estimated PrEP unit cost is $10,249 based on the 2015 dispensed price for maximum quantity (DPMQ) of tenofovir with emtricitabine on the Pharmaceutical Benefits Scheme website (see Tables A1-A3 in the Appendix). We assessed lower unit costs needed for PrEP to be cost-effective.
- We assumed three years for scale up to reach the usage coverage levels based on the clinical capacity and experience of rolling out PrEP programs in jurisdictions during 2016, and assessed the impact of scaling up in shorter periods.
- A high level of 90% adherence was assumed based on emerging evidence from Australian demonstration projects, including measures based on biological assays in the PRELUDE study which were presented at the ASHM conference in 2016 (Zablotska, 2016). We also assessed the impact of PrEP if there were lower levels of adherence (70%, 50% and 30%) and assumed efficacy at these lower levels based on the Anderson et al study [18] which estimated an HIV-1 risk reduction of 99% for seven doses per week, 96% for four doses per week, and 76% for two doses per week.
- We estimated the unit cost required for the PrEP intervention to become cost-effective at $30,000, $60,000 and $90,000 willingness-to-pay thresholds (Table 4) as well as the total cost (Table 5). Willingness-to-pay thresholds are a subjective value determining whether a program is ‘cost effective’ or if it is ‘cost effective’ to switch from one program to another and reflects the maximum amount the health sector is willing to pay to procure a good or avoid something undesirable. These three thresholds were selected to encompass a broad range of potential outcomes as the Pharmaceutical Benefits Advisory Committee (PBAC) does not use a specific cost-effectiveness threshold for inclusion onto the PBS.
- Based on data from the Gay Periodic Survey, at baseline we assumed 47% and 42% of high-risk gay men taking PrEP used condoms with casual and regular partners respectively, and assessed the impact if condom use decreased by 10%, 30% and 50% (for those taking PrEP and overall).
Projected impact of PrEP on reductions in new HIV infections

The HIV model showed that PrEP interventions are projected to have a large impact on new HIV infections over 2016-2030 particularly if a high coverage is reached in the high-risk gay men, who make up 28.2%, or 31,700 (range: 25,400-38,100) of HIV-negative gay men (Table A7 and Figure A8 in the Appendix). Expanding PrEP to medium-risk gay men reduces new infections minimally due to the relatively small population size of medium risk men, as defined in the ASHM guidelines. Expanding PrEP to low-risk gay men does result in some additional new infections averted but this is small relative to the population size (67.8% of all HIV-negative gay men).

Cost-effectiveness considering different PrEP usage scenarios

Table 4 shows the PrEP unit cost needed for difference usage scenarios to be cost-effective and willingness to pay thresholds and Table 5 shows the total costs of these scenarios to the health system.

Considering the middle $60,000 threshold, the current estimated PrEP unit cost (of $10,249) would need to fall by 35-52% for the scenarios in which PrEP is used only be high-risk gay men to be cost-effective, this would result in an incremental cost per annum of $7,186,000-$17,107,000 considering 9,450-28,350 gay men will receive it (in 2016).

For the Scenario90-0-0 (where coverage in restricted to 90% of high-risk men only) the unit cost would need to be $4,960 (incremental cost per annum of $17,107,000), ranging from $3,750 to $6,170 for the lower and upper thresholds, respectively.

For the scenario (90-20-10) where PrEP is provided to 90% of high-risk men, 20% of medium risk men and 10% of low-risk men, PrEP unit cost would have to fall to $3,730, or total incremental costs per year of $18,422,000.

In a scenario where PrEP coverage further expands to medium-risk men (Scenario90-60-0) the unit cost needs to be $4,500, and when it expands to medium and low risk gay men (Scenario90-60-30), the unit cost would need to be $2,570 to be cost effective, or total incremental costs per year of $19,647,000.

Finally in a scenario where 90% of all gay men (high, medium and low) received PrEP (Scenario90-90-0, the PrEP unit cost would have to fall to below $1,600 per year (or total incremental costs per year of $24,153,000 for all men) at the $60,000 willingness-to-pay threshold.

PrEP is more cost-effective if it is prioritized to men at highest risk of HIV. When coverage is expanded to medium-risk men (Scenario90-60-0) the unit cost needed to be cost effective only drops moderately by a further 9.3%, compared to Scenario90-0-0, however when coverage is expanded to low-risk risk men (Scenario90-60-30), the unit price needs to drop considerably, by a further 44.6% to be cost effective, compared to Scenario90-0-0.
Table 4: PrEP unit cost required per year to be cost effective at three different willingness-to-pay threshold, for all the usage scenarios. Ranges available in Table A8 of the appendix.

<table>
<thead>
<tr>
<th>Percent of gay men receiving PrEP, by HIV risk</th>
<th>Willingness to pay threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30k per QALY</td>
</tr>
<tr>
<td>High-risk 30%</td>
<td>$4,910</td>
</tr>
<tr>
<td>High-risk 60%</td>
<td>$4,290</td>
</tr>
<tr>
<td>High-risk 90%</td>
<td>$3,750</td>
</tr>
<tr>
<td>Medium-risk 90%</td>
<td>$3,640</td>
</tr>
<tr>
<td>Low-risk 90%</td>
<td>$3,410</td>
</tr>
<tr>
<td>High-risk 30%</td>
<td>$2,820</td>
</tr>
<tr>
<td>Medium-risk 60%</td>
<td>$1,940</td>
</tr>
<tr>
<td>Low-risk 60%</td>
<td>$1,190</td>
</tr>
</tbody>
</table>

Table 5: Total costs to health system.

<table>
<thead>
<tr>
<th>Percent of gay men receiving PrEP, by HIV risk</th>
<th>Unit cost to be cost-effective at 60k per QALY</th>
<th>Average annual incremental cost 2016-2030 (nearest $1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-risk 30%</td>
<td>$6,560</td>
<td>$7,186,000</td>
</tr>
<tr>
<td>High-risk 60%</td>
<td>$5,680</td>
<td>$12,956,000</td>
</tr>
<tr>
<td>High-risk 90%</td>
<td>$4,960</td>
<td>$17,107,000</td>
</tr>
<tr>
<td>Medium-risk 90%</td>
<td>$4,810</td>
<td>$17,260,000</td>
</tr>
<tr>
<td>Low-risk 90%</td>
<td>$4,500</td>
<td>$17,351,000</td>
</tr>
<tr>
<td>High-risk 30%</td>
<td>$3,730</td>
<td>$18,422,000</td>
</tr>
<tr>
<td>Medium-risk 60%</td>
<td>$2,570</td>
<td>$19,647,000</td>
</tr>
<tr>
<td>Low-risk 60%</td>
<td>$1,560</td>
<td>$24,153,000</td>
</tr>
</tbody>
</table>
(iv) Variation in cost-effectiveness estimates considering scenarios of unit cost, adherence, usage patterns, speed of scale up and condom use

a. **Unit cost:** If we assumed the agreed generic price of PrEP is $1000 per unit (around 10% of the current PBS cost), then all the PrEP scenarios would be cost—effective, and the Scenario90-0-0 would be cost-saving (see Appendix Figure A11).

b. **Adherence:** Reducing adherence to moderate levels only slightly reduces the epidemiological impact of the PrEP intervention. This is because PrEP efficacy does not reduce substantially until the number of pills taken per week falls below three with efficacy remaining at 75% even if only two pills are taken per week (assumed efficacy for 7, 5, 3, 1 pills per week is 99%, 97%, 90%, 77%, 45% respectively; Figure A7 in the Appendix). Given efficacy is maintained despite a lower adherence, this has the effect of greatly increasing the cost-effectiveness of PrEP (as the PrEP costs are lower as men require fewer pills per year) (Figure A12 and Table A9 in the Appendix). If a lower adherence reflected men were taking PrEP on ‘demand’ then such a scenario would be even more cost-effective (as long as PrEP was taken at the appropriate time, so that high levels of efficacy are maintained).

c. **Scale up duration:** Taking less than three years to reach the intervention coverage increases the impact and cost-effectiveness of PrEP interventions. This highlights the importance of scaling up PrEP programs as fast as possible to maximize the benefit (Figure A15 and Table A11 in the Appendix).

d. **Condom use:** If the presence of a PrEP program reduces the level of condom use in gay men taking PrEP, then we project only a small increase in new infections overall (compared to the no risk compensation scenario) and a corresponding small reduction in cost-effectiveness. This is because at high adherence PrEP is highly effective at preventing HIV transmission and essentially replaces the need for condoms with respect to reduction in HIV transmission risk. However, such a scenario would likely lead to an increase in other sexually transmitted infections (not costed here). However, an initial increase in new HIV infections could occur before PrEP is completely rolled-out (Figure A13 in the Appendix). If there is a reduction condom use across all gay men, even in those not taking PrEP—potentially due to a general belief of lower risk—then the effect of PrEP will be reduced slightly but will not counteract the overall benefits of PrEP (Figure A14 and Table A10 in the Appendix).
References


APPENDIX 2 – Modelled HIV incidence with varying PrEP access – by Epidemiologist Nick Scott, the Burnet Institute, Victoria

Table 6: HIV Notifications in Australia 2010–2015 and projections under various scenarios. Percentages are relative to the number of HIV notifications in 2010 (1043).

<table>
<thead>
<tr>
<th>Year</th>
<th>HIV notifications</th>
<th>Maintain status quo</th>
<th>95-95-95 by 2020</th>
<th>95-95-95 by 2020 + PrEP (75% eligible)</th>
<th>95-95-95 by 2020 + PrEP scale-up (to 80% eligible by 2020)</th>
<th>95-95-95 by 2020 + PrEP (85% eligible)</th>
<th>95-95-95 by 2020 + PrEP (90% eligible)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>1043 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>1050 (101%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>1065 (102%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>1030 (99%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>1082 (104%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>1025 (98%)</td>
<td>1025 (98%)</td>
<td>1025 (98%)</td>
<td>1025 (98%)</td>
<td>1025 (98%)</td>
<td>1025 (98%)</td>
<td>1025 (98%)</td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td>1025 (98%)</td>
<td>939 (90%)</td>
<td>784 (75%)</td>
<td>774 (74%)</td>
<td>764 (73%)</td>
<td>754 (72%)</td>
</tr>
<tr>
<td>2017</td>
<td>1064 (102%)</td>
<td>881 (84%)</td>
<td>708 (68%)</td>
<td>697 (67%)</td>
<td>685 (66%)</td>
<td>674 (65%)</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>1105 (106%)</td>
<td>814 (78%)</td>
<td>628 (60%)</td>
<td>616 (59%)</td>
<td>604 (58%)</td>
<td>592 (57%)</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>1147 (110%)</td>
<td>738 (71%)</td>
<td>547 (52%)</td>
<td>534 (51%)</td>
<td>522 (50%)</td>
<td>509 (49%)</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>1191 (114%)</td>
<td>654 (63%)</td>
<td>464 (44%)</td>
<td>452 (43%)</td>
<td>439 (42%)</td>
<td>427 (41%)</td>
<td></td>
</tr>
</tbody>
</table>
Figure A1: Baseline HIV incidence projection for Australia. Status-quo scenario assumes no PrEP scale-up and that no improvements are made to the percentage of people with HIV who are diagnosed or on treatment.

Figure A2: Projected HIV incidence with 95-95-95 target by 2020 (dashed blue line), and 95-95-95 target + 80% of eligible men who have sex with men on PrEP by 2020 (dotted blue line). This is based on the assumption that by 2020, 95% of all people living with HIV will know their HIV status, 95% of all people diagnosed with HIV will receive sustained antiretroviral therapy, and 95% of all people receiving antiretroviral therapy will have viral suppression, which means that they cannot
transmit HIV through sexual contact (the “95-95-95 target”). The status-quo scenario (solid blue line) is the same as Figure A1.

![Modelled HIV incidence](image)

*Figure A3: Effect based on different levels of scale-up of PrEP, ranging from 75–90%. The status-quo (solid blue line) and 95-95-95 by 2020 (dashed blue line) scenarios are the same as Figure A1 and A2 respectively.*